KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Castle Biosciences (CSTL) Net Margin (2018 - 2026)

Castle Biosciences' Net Margin history spans 8 years, with the latest figure at 2.68% for Q4 2025.

  • On a quarterly basis, Net Margin fell 1379.0% to 2.68% in Q4 2025 year-over-year; TTM through Dec 2025 was 7.02%, a 1251.0% decrease, with the full-year FY2025 number at 7.02%, down 1251.0% from a year prior.
  • Net Margin hit 2.68% in Q4 2025 for Castle Biosciences, down from 0.6% in the prior quarter.
  • Over the last five years, Net Margin for CSTL hit a ceiling of 11.11% in Q4 2024 and a floor of 91.7% in Q1 2022.
  • Historically, Net Margin has averaged 24.75% across 5 years, with a median of 15.0% in 2021.
  • Biggest five-year swings in Net Margin: plummeted -7294bps in 2022 and later soared 6600bps in 2024.
  • Tracing CSTL's Net Margin over 5 years: stood at 53.44% in 2021, then dropped by -1bps to 53.78% in 2022, then surged by 93bps to 3.9% in 2023, then surged by 385bps to 11.11% in 2024, then crashed by -124bps to 2.68% in 2025.
  • Business Quant data shows Net Margin for CSTL at 2.68% in Q4 2025, 0.6% in Q3 2025, and 5.25% in Q2 2025.